Hit identification

#Artificial intelligence (AI) #Automation / robotics #Drug discovery #Hit identification #Hit to lead

Unlocking hit-to-lead efficiency through AI and automation

Veronica DeFelice, Director of Biologic Products at Sapio Sciences, looks at how the hit-to-lead process in drug discovery is being impacted by AI and automation. Complexity at the core of hit-to-lead Hit-to-lead (H2L) screening is a critical phase in drug discovery, where researchers narrow down large libraries of compounds, small… Read More

#Exclusive Content

Peptide
#Cancer research #Collaboration #Evergreen Discovery #Hit identification #Orbit Discovery #Partnership #Peptides

Companies partner to identify cell targeting peptides

Companies Evergreen Discovery and Orbit Discovery have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals. The agreement covers activities including designing peptide libraries, hit identification and hit validation to confirm cell surface binding properties. The… Read More

#Business & Investment #News

Molecules
#Drug discovery #Fragment-based drug discovery #Hit identification

Introduction into FBDD webinar: last chance to register

Don’t miss your chance to register for the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. The event will take place on Thursday, October 13 at 3PM BST, 4PM CET, 10AM EST, 7AM PDT. Attendees will learn:… Read More

#News

#Drug discovery #Fragment-based drug discovery #Hit identification

Understand the role of fragment-based drug discovery: webinar

Fragment-based drug discovery (FBDD) is one strategy used to identify novel and potent lead compounds.   Don’t miss out on this free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragments are small molecules with a low molecular weight (less than… Read More

#News

#Drug discovery #Fragment-based drug discovery #Hit identification

Webinar: Introduction into Fragment Based Drug Discovery

Fragment-based drug discovery (FBDD) is one strategy of hit identification (hit ID) in the drug discovery process. Watch the webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Key Learning Objectives:   How FBDD can help identify novel and potent lead… Read More

#News

#Drug discovery #Fragment-based drug discovery #Hit identification

Discover the benefits of fragment-based drug discovery

Watch the free webinar, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec. Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process. Fragments are small molecules… Read More

#News

Molecules
#Drug discovery #Fragment-based drug discovery #Hit identification #Webinar

An introduction into fragment-based drug discovery: webinar

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec, is now available to watch online. … Read More

Webinar date:
Brought to you by WuXi AppTec
#Webinars

Molecules
#Drug discovery #Fragment-based drug discovery #Hit identification

An introduction into fragment-based drug discovery: webinar

Fragment-based drug discovery (FBDD) is a method used for finding hit compounds as one strategy of hit identification (hit ID) in the drug discovery process.   Watch this free event, Introduction into Fragment Based Drug Discovery, hosted by DDW and supported by WuXi AppTec.  Fragments are… Read More

#News

#Drug discovery #Genetic editing #Hit identification #Medicinal chemistry #Podcast

Using biotechnology to maximise drug discovery output – podcast 

The latest free-to-listen DDW podcast episode is titled “Using biotechnology to maximise drug discovery output”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “The important integration of medicinal chemistry in Hit-to-Lead… Read More

#News

#Biotechnology #Drug discovery #Drug targets #Hit identification #Immunotherapy #Oncology

Partnership will progress targeted cancer immune therapy drug discovery

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an… Read More

#Cancer Research #News